Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
|Articles|March 1, 1996
Supplements and Featured Publications
- Calcium Channel Blockers: 1995 -- The Year in Review
- Volume 2
- Issue 4 Suppl
Participants
Advertisement
Articles in this issue
over 30 years ago
Calcium Channel Blockers: 1995 - An Overviewover 30 years ago
Safety of Calcium Channel Blockers: Results of Recent Trialsover 30 years ago
Calcium Channel Blockers: New Trials and Trials in Progressover 30 years ago
Are Calcium Channel Blockers Prohemorrhagic?over 30 years ago
A Provocative Interpretation of the Case Control Analysisover 30 years ago
Shades of Opinion: What Is Prudent?Advertisement
Related to this article
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.
AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.
IDWeek 2026 posters describe a rule-based tool classifying about 1 in 5 patients with cUTI as outpatient-eligible and 5 clusters with varied LOS.
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.
An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
International Panel Agrees on Framework for Tapering Psoriasis Biologics
4
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
5